Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study

Abstract

To the Editor: While immune checkpoint inhibitors (ICIs) against cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been at the forefront of metastatic melanoma treatment, they commonly induce immune-related adverse events, such as cutaneous adverse events (CAEs). Many studies on CAEs have been previously restricted to individual types of CAEs or classes of ICIs.1-3 As the CTLA-4 and PD-1 molecules are implicated in different interactions, we comprehensively examined the characteristics of all CAEs and their associations with treatment outcome to shed light on potential mechanisms for CAEs irrespective of the ICI therapy.